Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Mark Freitas
CDMO Platforms Will Be The Central Arena For MedTech M&A In 2026
Alvarez & Marsal are most popular: within Law Department Performance topic(s) As market conditions stabilize and capital begins to re-engage, contract development and manufacturing organizations (CDMOs) are emerging as central drivers of value creation across the MedTech ecosystem. In 2026, the convergence of financial clarity, strategic repositioning, and platform scale ambition is expected to redefine how OEMs and investors approach growth, partnerships, and M&A in the sector.
The Profit Crunch: How US Policy Could Reshape Global Pharma Research And Development (R&D)
Alvarez & Marsal are most popular: within Insolvency/Bankruptcy/Re-Structuring, Criminal Law and Law Practice Management topic(s) US pharmaceutical companies have long been a dominant force in global foreign direct investment (FDI), contributing around 25% of outbound FDI in the sector and over half of global pharmaceutical research and development (R&D) spending.1 This leadership is rooted in the strong profitability of the US market.
CRLs Unveiled: Converting FDA Transparency Into A Market Advantage
CRLs Unveiled: Converting FDA Transparency Into A Market Advantage With the FDA's disclosure of 200 Complete Response Letters (CRLs), leadership teams now have an unprecedented insight into regulatory decision-making to glean patterns... United States Food, Drugs, Healthcare, Life Sciences To print this article, all you need is to be registered or login on Mondaq.com.
Most-Favored-Nation: Weak Policy, Strong Signal
MFN may never become law, but its signal still matters The industry is still parsing the implications of the new MFN framework established by May's Executive Order. While practical policy details remain undefined, the signal is unmistakable: the administration wants to bring pharma to the table on drug pricing. The real question is how the industry responds. Does it see MFN as a threat that it must navigate or as an opportunity to lead?
What If The Biosimilar Wave Is Just A Ripple?
The swell that may not break Where biosimilars stand now A record-breaking patent cliff is on the horizon, but headwinds may shrink the anticipated "wave" to a ripple. While past launches were a smash hit, recent ones are a wake-up call. Why the water's so choppy What's holding biosimilars back? There are three main culprits holding things back: policy uncertainty from the Inflation Reduction Act (IRA), tricky reimbursement economics, and PBMs acting as gatekeepers.
Next-Generation Antibodies: A New Era In Immuno-Oncology
Next-Generation Antibodies: A New Era In Immuno-Oncology As the immune checkpoint inhibitor (ICI) market nears a patent cliff, the $50B immuno-oncology (IO) field is now seeking to surpass the limitations of earlier ICIs by enhancing survival outcomes...
Unlocking New Value In The Biopharma Cold Chain
Our latest industry report dives deep into the trends driving growth, from the rise of temperature-sensitive biologics to the technological advancements reshaping logistics. With a projected 13% annual growth rate, the biopharma cold chain is not just growing—it's transforming. Learn how strategic investments in packaging, transportation, warehousing, and monitoring can position your company for success in this dynamic landscape.
Unlocking The Potential Of Generative AI In Pharma
Generative AI is no longer just a buzzword—it's a transformative force in the life sciences industry. As businesses move beyond the initial hype, they are uncovering practical ways to leverage this technology for tangible results. From streamlining drug discovery to enhancing patient engagement, the potential applications are vast and impactful. The Hemingway Effect in Gen AI: Understand the historical journey and the pivotal advancements that have brought generative AI to the forefront.
Is The Season Over for The Ottawa Senators?
As of now, the Ottawa Senators rank 32nd in the NHL with a 4-14-1 record and a .237 win percentage. They have lost five in a row, including getting swept in the annual California road trip. They are five points behind the struggling Montreal Canadiens and a full ten points behind the Jack Eichel-less Buffalo Sabres. Aside from the top-line of Brady Tkachuk, Josh Norris, and Drake Batherson, nearly the entire forward group is lagging behind.
Tanking This Year Is Not The End Of The World For The Senators
The Ottawa Senators have been in a rebuild for 4 years now, and while GM Pierre Dorion has claimed that the rebuild is over, it does not seem that way with an under .500 record. The team has struggled with injuries, defensive performance and has been hit with a COVID-19 outbreak. There is still some work to do. With Shane Pinto and Colin White out for most of the year, the depth down the middle has been depleted to Josh Norris, Chris Tierney, Nick Paul and Logan Shaw.
NXT Playback Hosted By Mark Freitas
What's the latest in the black and gold brand...??? Mark Freitas has the latest...
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Mark
Contact Mark, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack